Immunocore Holdings PLC (IMCR) — 8-K Filings

8-K Filings (25)

• 8-K Filing — May 6, 2026
• Immunocore Reports Director/Officer Changes — Nov 28, 2025 Risk: low
  Immunocore Holdings plc filed an 8-K on November 28, 2025, reporting changes as of November 26, 2025. The filing pertains to the departure of directors or certa
• Immunocore Holdings plc Files 8-K on Financials — Nov 6, 2025 Risk: low
  Immunocore Holdings plc filed an 8-K on November 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• Immunocore Files 8-K on Financials and Exhibits — Aug 7, 2025 Risk: low
  Immunocore Holdings plc filed an 8-K on August 7, 2025, reporting on its Results of Operations and Financial Condition, and submitting Financial Statements and
• Immunocore Holdings plc Files 8-K on Security Holder Vote — May 15, 2025 Risk: low
  Immunocore Holdings plc filed an 8-K on May 15, 2025, reporting on a submission of matters to a vote of security holders. The filing details the company's corpo
• Immunocore Holdings plc Files 8-K on Financials — May 7, 2025 Risk: low
  Immunocore Holdings plc filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements an
• Immunocore Files 8-K for Other Events — Mar 17, 2025 Risk: low
  Immunocore Holdings plc filed an 8-K on March 17, 2025, to report other events and financial statements. The filing does not contain specific details about the
• Immunocore Holdings plc Files 8-K — Mar 10, 2025 Risk: low
  Immunocore Holdings plc filed an 8-K on March 10, 2025, reporting on its activities. The filing primarily concerns financial statements and exhibits, with no sp
• Immunocore Files 8-K on Operations, Personnel Changes — Feb 26, 2025 Risk: medium
  Immunocore Holdings plc filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing also disclosed the departu
• Immunocore Files 8-K on Financials and Operations — Jan 10, 2025 Risk: low
  Immunocore Holdings plc filed an 8-K on January 10, 2025, to report on its results of operations and financial condition, as well as other events and Regulation
• Immunocore Holdings plc Files 8-K with Corporate Updates — Jan 2, 2025 Risk: low
  Immunocore Holdings plc filed an 8-K on January 2, 2025, reporting events as of December 31, 2024. The filing indicates changes in directors or officers, potent
• Immunocore Terminates Material Definitive Agreement — Nov 8, 2024 Risk: medium
  Immunocore Holdings plc announced on November 8, 2024, the termination of a material definitive agreement. The company, incorporated in England and Wales, is in
• Immunocore Files 8-K on Operations and Financials — Nov 6, 2024 Risk: low
  Immunocore Holdings plc filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition, as well as filing financial statements
• Immunocore Files 8-K: Other Events & Financials — Sep 16, 2024 Risk: low
  Immunocore Holdings plc filed an 8-K on September 16, 2024, reporting on events that occurred on September 14, 2024. The filing includes information on "Other E
• Immunocore Appoints New CMO and CFO — Aug 29, 2024 Risk: medium
  Immunocore Holdings plc announced on August 28, 2024, the appointment of Dr. Joern Hoch as Chief Medical Officer and Ms. Sarah O'Connor as Chief Financial Offic
• Immunocore Holdings plc Files 8-K on Financials — Aug 8, 2024 Risk: low
  Immunocore Holdings plc filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing details financial statements
• Immunocore Files 8-K for Disclosure and Exhibits — May 31, 2024 Risk: low
  Immunocore Holdings plc filed an 8-K on May 31, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Immunocore Partners with Genmab for Cancer Therapies — May 30, 2024 Risk: medium
  Immunocore Holdings plc announced on May 29, 2024, that it has entered into a strategic collaboration with Genmab A/S. This collaboration focuses on the discove
• Immunocore Appoints New CMO, Elects Director — May 28, 2024 Risk: low
  Immunocore Holdings plc announced on May 28, 2024, the appointment of Dr. Joanna Horobin as Chief Medical Officer and the election of Dr. Richard J. Davies to i
• Immunocore Files 8-K on Security Holder Vote — May 23, 2024 Risk: low
  Immunocore Holdings plc filed an 8-K on May 23, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain spec
• Immunocore Files 8-K with Corporate Updates — Apr 5, 2024 Risk: low
  Immunocore Holdings plc filed an 8-K on April 5, 2024, reporting other events and financial statements. The filing details the company's principal executive off
• Immunocore Reports Material Agreement, New Debt, Equity Sales — Feb 2, 2024
  Immunocore Holdings plc filed an 8-K on February 2, 2024, reporting an event on January 30, 2024, related to entering a material definitive agreement, creating
• Immunocore Files 8-K on Operations & Financial Condition — Jan 29, 2024
  Immunocore Holdings plc filed an 8-K on January 29, 2024, to report on its results of operations and financial condition, as well as other events. This filing i
• Immunocore Confirms NASDAQ Listing of ADSs in 8-K Filing — Jan 5, 2024
  Immunocore Holdings plc filed an 8-K on January 5, 2024, to announce that its American Depositary Shares, each representing one ordinary share with a nominal va
• Immunocore Signals Major Corporate Event via SEC Filings — Jan 2, 2024
  Immunocore Holdings plc filed an 8-K on January 2, 2024, indicating that it is making written communications pursuant to Rule 425 under the Securities Act, soli

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX